Fulgent Genetics Q2 2024 Adj. EPS $0.15 Beats $(0.30) Estimate, Sales $71.028M Beat $69.066M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fulgent Genetics reported Q2 2024 adjusted EPS of $0.15, significantly beating the estimated loss of $(0.30). Sales also surpassed expectations, coming in at $71.028 million compared to the $69.066 million estimate.
August 02, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fulgent Genetics reported better-than-expected Q2 2024 results with an adjusted EPS of $0.15, beating the $(0.30) estimate, and sales of $71.028 million, surpassing the $69.066 million estimate.
The significant beat on both EPS and sales estimates is likely to positively impact FLGT's stock price in the short term as it indicates strong financial performance and operational efficiency.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100